Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

The Journal of Thoracic and Cardiovascular Surgery

article

Valerie W. Rusch¹  Alan Nicholas²  G. Alexander Patterson³  Salama N. Waqar³  Eric M. Toloza⁴  Eric B. Haura⁴  Dan J. Raz⁵  Karen L. Reckamp⁵  Robert E. Merritt⁶  Dwight H. Owen⁶  David J. Finley⁷  Ciaran J. McNamee⁸  Justin D. Blasberg⁹  Edward B. Garon^1,10  John D. Mitchell^1,11  Robert C. Doebele^1,11  Frank Baciewicz^1,12  Misako Nagasaka^1,13  Harvey I. Pass^1,14  Katja Schulze²  Ann Johnson²  Paul A. Bunn^1,11  Bruce E. Johnson^1,15  Mark G. Kris¹  David J. Kwiatkowski⁸  Ignacio I. Wistuba^1,16  Jamie E. Chaft¹  David P. Carbone⁶  Jay M. Lee^1,17 

[1] Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College;Genentech, Inc;Washington University School of Medicine;H. Lee Moffitt Cancer Center;Cedars Sinai, previously City of Hope Comprehensive Cancer Center;The Ohio State Medical Center and the Pelotonia Institute for Immune Oncology;Dartmouth-Hitchcock Medical Center;Brigham and Women"s Hospital;Yale School of Medicine;David Geffen School of Medicine at UCLA;University of Colorado Cancer Center;Wayne State University;Karmanos Cancer Institute;New York University;Dana-Farber Cancer Institute;The University of Texas MD Anderson Cancer Center;David Geffen School of Medicine at UCLA, Los Angeles, Calif关键词: immunotherapy;    lung cancer;    neoadjuvant therapy;   

DOI  :  10.1016/j.jtcvs.2022.10.007

学科分类：心脏病和心血管学

来源: Mosby, Inc.

【 摘 要 】

Multimodality treatment for resectable non–small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non–small cell lung cancer and promising preoperatively in small clinical trials for resectable non–small cell lung cancer. This large multicenter trial tested the safety and efficacy of neoadjuvant atezolizumab and surgery.

【 授权许可】

Unknown